Oct 9 (Reuters) - Fresenius SE & Co KGaA ::FRESENIUS KABI BIOSIMILAR CANDIDATE MEETS PRIMARY ENDPOINTS IN THE TWO PIVOTAL CLINICAL STUDIES.FRESENIUS KABI HAS REACHED A MILESTONE ON THE ROAD TO APPROVAL FOR ANOTHER BIOSIMILAR.MSB11455, A BIOSIMILAR CANDIDATE FOR NEULASTA® (PEGFILGRASTIM), HAS MET ITS PRIMARY ENDPOINTS IN THE TWO PIVOTAL CLINICAL STUDIES.
Full Article
Oct 1 (Reuters) - Akorn Inc ::AKORN COMMENTS ON DELAWARE CHANCERY COURT RULING.AKORN INC - "CONTINUE TO BELIEVE FRESENIUS' ATTEMPT TO TERMINATE TRANSACTION IS IN BREACH OF OUR BINDING MERGER AGREEMENT".AKORN INC - "INTEND TO APPEAL, IN AN EFFORT TO VIGOROUSLY ENFORCE OUR RIGHTS".
Full Article
July 31 (Reuters) - Fresenius Se ::CEO SAYS ARE CONVINCED OF MERITS OF CASE TO TERMINATE AKORN DEAL.CEO SAYS EVEN IF COURT DOES NOT AGREE IT WAS THE RIGHT DECISION TO TERMINATE DEAL.CEO SAYS EXPECTS AKORN MATTER TO BE FINALLY RESOLVED BY EARLY NEXT YEAR.CFO SAYS LESS LIKELY TO REACH UPPER END OF 2018 SALES GUIDANCE OF 5-8 PERCENT.CEO SAYS IF WE ARE FORCED TO CLOSE AKORN DEAL, WILL NEED TO DO SOME PRETTY SUBSTANTIAL REMEDIATION REGARDLESS OF HOW FDA RESPONDS.
Full Article
July 18 (Reuters) - NxStage Medical Inc ::NXSTAGE MEDICAL INC - ON JULY 10, CO AGREED TO SELL ITS BLOODLINES BUSINESS OPERATED UNDER THE MEDISYSTEMS NAME TO B. BRAUN MEDICAL INC.NXSTAGE MEDICAL INC - NXSTAGE CONTINUES TO EXPECT FRESENIUS MERGER TO CLOSE IN 2018 -SEC FILING.
Full Article
April 22 (Reuters) - Akorn Inc ::AKORN INC ISSUES STATEMENT IN RESPONSE TO FRESENIUS KABI’S ANNOUNCEMENT THAT IT IS SEEKING TO TERMINATE THE DEFINITIVE MERGER AGREEMENT.AKORN SAYS PREVIOUSLY DISCLOSED ONGOING INVESTIGATION HAS NOT FOUND ANY FACTS THAT WOULD RESULT IN ADVERSE EFFECT ON CO'S BUSINESS.AKORN SAYS SINCE INVESTIGATION DID NOT FIND ANY FACTS RESULTING IN ADVERSE EFFECT ON CO'S BUSINESS, IT IS "NO BASIS TO TERMINATE THE TRANSACTION".AKORN SAYS INTEND TO "VIGOROUSLY" ENFORCE CO'S RIGHTS, AND FRESENIUS’ OBLIGATIONS, UNDER BINDING MERGER AGREEMENT.
Full Article
April 22 (Reuters) - Fresenius SE & Co KGaA ::DGAP-ADHOC: FRESENIUS SE & CO. KGAA: FRESENIUS TERMINATES MERGER AGREEMENT WITH AKORN.
Full Article
Dec 22 (Reuters) - Fresenius Se ::NEW US TAX LEGISLATION TRIGGERS REVALUATION OF DEFERRED TAX LIABILITIES.US TAX REFORM RESULTS IN A ONE-TIME BOOK GAIN OF APPROXIMATELY EUR 90 MILLION, TO BE REFLECTED IN FRESENIUS' 2017 GROUP NET INCOME.WILL REPORT FY17 RESULTS, PROVIDE FY18 GUIDANCE, INCLUDING DETAILS ON RECURRING TAX EFFECTS RESULTING FROM US TAX REFORM, ON FEB 27, 2018.
Full Article
Earnings vs. 
Estimates